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Apnea of prematurity is a common complication in prema-
ture infants. The first-line pharmacotherapeutic agent for
this condition is caffeine, a methylxanthine. Caffeine is
preferred over theophylline because it has fewer adverse
effects and a wider therapeutic window.1 Measuring the
serum caffeine concentration is not required in preterm
neonates because most of these infants can tolerate ther-
apeutic levels.2 In this paper, we present the first report of
a preterm neonate in whom the serum caffeine concen-
tration exceeded therapeutic levels, which resulted in
rhabdomyolysis.2. Case Report
A female infant weighing 1028 g was born at 28 weeks of
gestation by cesarean section. Her Apgar scores were 2 at 1
minute and 6 at 5 minutes. She was intubated, adminis-
tered a single dose of surfactant, and placed on mechanical
ventilation for 2 days because of respiratory distress
syndrome.
On the 2nd day, hemodynamically significant patent
ductus arteriosus was diagnosed, based on echocardiogra-
phy. Treatment was initiated with a starting dose of* Corresponding author. Division of Neonatology, Maternal and
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Toyama 930-0194, Japan.
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doses of 0.1 mg/kg at a 24-hour interval.
After extubation, she experienced episodes of apnea on
the 3rd day. Caffeine therapy was initiated with a bolus
dose of 20 mg/kg, followed by daily maintenance doses of
5 mg/kg. On the 8th day, the caffeine dose was increased to
9 mg/kg because of recurrent apnea. However, because she
developed tachycardia (heart rate, 180 beats per minute),
we reduced the caffeine dose to 7 mg/kg on the 12th day.
Her apnea was well controlled thereafter and caffeine
therapy was continued at 7 mg/kg. Her serum creatinine
kinase (CK) levels increased from 83 U/L (on Day 6) to
659 U/L (on Day 17). However, she did not exhibit any
associated jitteriness or seizure. On the 18th day, her urine
myoglobin concentration increased to 81.1 ng/mL, whereas
her serum caffeine concentration was 32.59 mcg/mL
(Figure 1).
She had no history of hypoxia, hypothyroidism, infec-
tion, or infarction, any of which could have increased the
serum CK levels. Moreover, she had no symptoms or family
history of myopathy. The elevated serum CK levels and
increased urine myoglobin concentration indicated
caffeine-related rhabdomyolysis.3 After reducing the
caffeine dose, her serum CK levels gradually returned to
normal, and she had no caffeine-related clinical symptoms.3. Discussion
This case of caffeine toxicity in a preterm neonate had two
important clinical features. First, the serum caffeine con-
centration exceeded the therapeutic levels, despite thein a Preterm Neonate, Pediatrics and Neonatology (2016), http://
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Figure 1 Clinical course of the patient. CKZ creatinine ki-
nase; SIMVZ synchronized intermittent mandatory ventila-
tion; SiPAPZ synchronized inspiratory positive airway
pressure.
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serum caffeine concentration for treating apnea of pre-
maturity is 8e20 mg/mL, whereas the toxic serum con-
centration is > 50 mg/mL; the half-life of caffeine is 72e96
hours in neonates.3 In our patient, the half-life of caffeine,
calculated from her serum caffeine concentration, was
determined as 245.2 hours. Based on this half-life, her
serum caffeine concentration was expected to become
much higher between the 8th day and 17th day (Figure 1).
Caffeine is metabolized by the hepatic cytochrome P-
450 monoxygenase pathway, but its activity is lower in
premature infants than in adults.4 Therefore, > 85% of the
administered caffeine dose is recovered unchanged in the
urine of an infant during the 1st month of life.4 A previous
study found that caffeine elimination was severely
depressed in extremely premature infants for the first 6
weeks after birth.5 In our patient, caffeine elimination was
prolonged because of her prematurity and young age at
which the caffeine was first administered. This prolonged
elimination could have caused the high serum caffeine
concentration.
Second, caffeine administration caused rhabdomyolysis
in our patient. The cutoff values of serum CK levels in
rhabdomyolysis remain controversial; however, the eleva-
tion of serum CK level by more than five-fold is an indicator
of rhabdomyolysis.6 Other frequent reasons for high serum
CK levelsdmyocardial infarction, thyroid dysfunction,
muscle injuries, and drugsdwere not noted. Several cases7
of caffeine overdose leading to rhabdomyolysis have been
reported in adults; however, there are no reports ofPlease cite this article in press as: Nakaoka S, et al., Caffeine Toxicity
dx.doi.org/10.1016/j.pedneo.2016.08.001caffeine-related rhabdomyolysis in neonates. Some reports
have described caffeine toxicity-related tachycardia,
tachypnea, irritability, jitteriness, and vomiting in preterm
neonates.1,3 When caffeine toxicity is suspected, clinicians
should assess the serum caffeine concentration and serum
CK levels. Caffeine is safely used in neonatal intensive care
units, although serum caffeine concentration may exceed
therapeutic levels and the additional administration of
caffeine may cause rhabdomyolysis in preterm newborns.
Further reports should be collated to confirm the correla-
tion between caffeine toxicity and rhabdomyolysis in pre-
term neonates.
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